None
Conditions
Interventions
Physiological saline group:None
Hyaluronic acid patch group:None
Upadacitinib Combined with Intense Pulsed Light Group (Retrospective):None
Intense Pulsed Light Group (Retrospective):None
Sponsors
Jingzhou Hospital affiliated to Yangtze University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Main project: (1) Age: 18 to 55 years old; (2) Fitzpatrick's skin classification is type II-IV. (3) Those who need to receive intense pulsed light therapy and whose postoperative care plan has been jointly decided by the doctor and the patient as either "Shengyi Medical Sodium Hyaluronate Wound Application" or "Normal Saline Application"; (4) Voluntarily sign the informed consent form and commit to cooperating to complete the 8-day follow-up (including telephone follow-up and on-site testing); (5) No other skin repair products were used within one month before the operation (to avoid interfering with the observation outcome). 2.Sub-project: (1) Female patients who visited the Dermatology Department of Jingzhou Central Hospital from March 2025 to October 2025; (2) Erythematous telangiectatic rosacea that meets the diagnostic criteria of ROSCO 2019; (3) Received upatinib combined with IPL treatment or IPL treatment alone; (4) It has complete clinical records before and after treatment and standardized facial photos.
Exclusion criteria
Exclusion criteria: 1.Main project : (1) Pregnancy/lactation period (hormone levels may affect wound healing and interfere with outcomes); (2) Those with a clear history of hypertrophic scars or keloids (high risk of postoperative scar formation, not related to the application effect); (3) History of photosensitivity (Severe erythema is prone to occur after surgery, which affects the judgment of adverse reactions); (4) There are active skin diseases at the treatment site (such as eczema or infection, which may confuse the repair effect); (5) Inability to cooperate with follow-up visits (such as long-term business trips or unstable contact information, resulting in data loss). 2.Sub-project: (1) Female patients who visited the Dermatology Department of Jingzhou Central Hospital from March 2025 to October 2025; (2) Erythematous telangiectatic rosacea that meets the diagnostic criteria of ROSCO 2019; (3) Received upatinib combined with IPL treatment or IPL treatment alone; (4) It has complete clinical records before and after treatment and standardized facial photos. 2.Sub project: (1)At the same time, receive other treatments that may affect the judgment of therapeutic effect (such as other phototherapy, systemic immunosuppressants); (2) Those with incomplete clinical data and unable to extract key data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Moisture content, texture, color spots, pigment, sensitivity; Symptoms of skin discomfort before and after application;relative intensity of redness;The Clinician's Erythema Assessment;Dermatology Life Quality Index ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of erythema area; | — |
Countries
China
Contacts
Public ContactYi Sun
Jingzhou Hospital affiliated to Yangtze University
Outcome results
None listed